All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Enfortumab Vedotin Plus Pembrolizumab Approved in Canada for Advanced Bladder Cancer

August 22nd 2024

Enfortumab vedotin plus pembrolizumab has been approved by Health Canada for use in unresectable locally advanced or metastatic urothelial cancer.

Fulzerasib Approved in China for KRAS G12C–Mutant Advanced NSCLC

August 22nd 2024

China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.

Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence

August 22nd 2024

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.

From Bench to Bedside: HIF-2α Inhibition in RCC

August 22nd 2024

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

Case Study Highlights an Approach to Adjuvant Treatment in RCC

August 22nd 2024

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

ODAC Vote Aims to Introduce Clarity on Phase of Treatment Benefits in Resectable NSCLC

August 22nd 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

A New Wave of Endocrine Therapies Are Emerging in HR+ Breast Cancer

August 21st 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma

August 21st 2024

Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.

Navigating the Complexities of Cancer Care

August 21st 2024

The Allegheny Health Network's comprehensive cancer navigation program supports all cancer patients from diagnosis to treatment and beyond.

PRECISION 1 Trial to End After Nab-Sirolimus is Projected to Miss Efficacy Threshold in TSC1/2+ Solid Tumors

August 21st 2024

Aadi Bioscience will end the PRECISION 1 trial evaluating nab-sirolimus in solid tumors harboring TSC1/2 alterations.

FDA Accepts sBLA for First-Line Nivolumab Plus Ipilimumab in Unresectable HCC

August 21st 2024

The FDA has accepted a supplemental biologics license application for nivolumab plus ipilimumab for first-line unresectable hepatocellular carcinoma.

FDA Issues Complete Response Letter to Linvoseltamab BLA in R/R Multiple Myeloma

August 21st 2024

The FDA has issued a CRL to the BLA seeking approval of linvoseltamab for use in select patients with relapsed or refractory multiple myeloma.

Cancer Care in 2024: Striving to Overcome the Challenges

August 21st 2024

Manmeet S. Ahluwalia, MD, MBA, FASCO, discusses ongoing efforts to overcome challenges in cancer care in 2024.

Repotrectinib Adds to the Treatment Armamentarium for NTRK+ Advanced Solid Tumors

August 21st 2024

Luis E. Raez, MD, FACP, FCCP, FASCO, discusses the FDA approval of repotrectinib for NTRK-positive advanced solid tumors.

Targeted Cancer Vaccines Could Shift the Paradigm for HPV+ HNSCC

August 21st 2024

Katharine A. Price, MD, discusses the use of HPV-targeted immunotherapy vaccines in patients with HPV16-positive head and neck squamous cell carcinoma.

Future Perioperative Trial Designs in NSCLC Need Adjustments Per FDA ODAC Consensus

August 20th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

The US Oncology Network Expands its Tennessee Service Area as Tennessee Cancer Specialists Joins The Network

August 20th 2024

Tennessee Cancer Specialists, the third largest oncology practice in the state, strengthens its ability to deliver cutting-edge advanced care by joining The Network.

FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer

August 20th 2024

GSK5764227 has received breakthrough therapy designation from the FDA for use in select patients with extensive-stage small cell lung cancer.

Sacituzumab Tirumotecan NDA for EGFR+ NSCLC Under Review in China

August 20th 2024

An NDA seeking approval of sacituzumab tirumotecan for select patients with EGFR+ non–small cell lung cancer has been accepted by the NMPA's CDE.

Enfortumab Vedotin Approved in China for Locally Advanced/Metastatic Urothelial Cancer

August 20th 2024

China’s National Medical Products Administration has approved enfortumab vedotin for adult patients with locally advanced or metastatic urothelial cancer.